|
home | contact us |
![]() |
Resources (Exclusive Benefit for CMOD Members and 2007 Symposium Registrants)
Read what the leading experts have to say about cardiovascular biomarkers, emerging data and initiatives. Learn about the importance of cardiovascular biomarkers in disease prevention, diagnosis, treatment, and research and development programs.
For membership information contact info@cmod.org.
Canadian Atherosclerosis Imaging Network (CAIN)
Global Atherothrombosis Investigative Network (GAIN)
GAIN is a unique organization of experienced investigators committed to working together toward a common goal – excellence in atherothrombosis research. With expertise ranging from basic research to the execution of clinical imaging studies and large international cardiovascular outcomes trials, GAIN is uniquely able to provide partnering organizations with the leadership and skills needed for the efficient and effective execution of research projects, and communication of the results. Areas of internationally recognized strengths include:
Experimental Medicine
Translational Medicine
Pharmacogenomics
Metabolomics and Proteomics
Lipids and Lipoproteins
Biomarker Development
Multi-modality Imaging Technologies
Positron Emission Tomography (PET)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Intravascular Ultrasound (IVUS)
Carotid Ultrasound (IMT and 3-D ultrasound of plaques)
International Randomized Clinical Outcomes Trials
Study Coordination – Project Management, Site Management and Monitoring
Clinical Endpoint Committee
Data Safety Monitoring Board
Publication and Communication
GAIN is pursuing collaborative research projects to evaluate the role of advanced technologies in the detection, assessment and monitoring of atherothrombotic disease, as well as the application of these technologies for the assessment of therapeutic interventions. GAIN has networks of sites on all continents and is supported by the Montreal Heart Institute Coordinating Centre (MHICC), a renowned academic research organization.
We would be pleased to discuss potential opportunities for collaboration. For more information, or to arrange a meeting, please contact Dr Therese Heinonen at 810-923-9108 or Dr Jean-Claude Tardif at 514-376-3330 ext.3612.
GAIN Collaborative Investigators:
Jean-Claude Tardif, M.D.
Director, MHI Research Centre, Montreal Heart Institute
Professor of Medicine, University of Montreal
Montreal, Canada
on behalf of the Global Atherothrombosis Investigative Network
Christie Ballantyne, M.D.
Professor of Medicine, Chief, Section of Atherosclerosis and Vascular Medicine,
Methodist DeBakey Heart and Vascular Center and Baylor College of Medicine,
Houston, TX, USA
Philip Barter, M.D., Ph.D.
Director of the Heart Research Institute
Sydney, Australia
Zahi Fayad, Ph.D.
Professor of Radiology and Medicine
Mount Sinai School of Medicine
New York, NY, USA
John J. P. Kastelein, M.D., Ph.D.
Chairman, Department of Vascular Medicine, Academic Medical Centre
University of Amsterdam
Amsterdam, the Netherlands
Wolfgang Koenig, M.D.
Professor of Medicine and Cardiology
University of Ulm Medical Center
Ulm, Germany
Ahmed Tawakol, M.D.
Program Leader, Cardiovascular Disease at the Center for Integration of Medicine and Innovative Technology, Massachusetts General Hospital, Harvard Medical School,
Boston, MA, USA
David Waters, M.D.
Professor of Medicine, University of California
San Francisco, CA
TRANSCRIPTS FROM PAST CARDIOVASCULAR BIOMARKER AND SURROGATE ENDPOINT SYMPOSIA
| Expert Speaker | Topic |
Eric P. Brass, M.D., Ph.D. |
The Balance Between Safety and Efficacy: Biomarkers as Safety Surrogates (2006) |
James De Lemos, M.D. |
Biomarkers in Heart Failure (2006) |
Zahi A. Fayad, Ph.D., FAHA, FACC |
In Vivo Imaging of Atherosclerosis by Multimodality MR, CT, and PET (2006) |
Timao Li, Ph.D. |
Canadian Regulatory View on Cardiovascular Biomarkers and Surrogate Endpoints in Clinical Trials (2006) |
Christopher O’Donnell, M.D. |
|
Gurvaneet Randhawa, MD, MPH |
Integrating Biomarkers into Practice: The Need for Data on Clinical Outcomes (2006) |
Norman Stockbridge, M.D. |
The Use of Biomarkers for FDA Regulatory Decision Making – Cardio-Renal (2006) |
Jean-Claude Tardif, M.D. |
The Role of Imaging in Disease Detection and Treatment (2006) |
Douglas C. Throckmorton, M.D. |
The FDA Critical Path Initiative – Opportunities and Challenges (2006) |
Paula Trumbo, Ph.D. |
The Use of Biomarkers for FDA Regulatory Decision Making – Health Claims (2006)
|
CMOD would like to thank Dan McKean and Sami Moubayed for their assistance in preparing these documents.
CURRENT GOOD MANUFACTURING PRACTICES FOR PET DRUG PRODUCTS IN THE UNITED STATES
